{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:38:27Z","timestamp":1786761507046,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2003,10]]},"DOI":"10.1016\/j.pnpbp.2003.09.006","type":"journal-article","created":{"date-parts":[[2003,11,5]],"date-time":"2003-11-05T21:55:06Z","timestamp":1068069306000},"page":"1101-1111","source":"Crossref","is-referenced-by-count":76,"title":["Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality"],"prefix":"10.1016","volume":"27","author":[{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2003.09.006_BIB1","first-page":"S165","article-title":"Atypical antipsychotics and memory function in patients with chronic schizophrenia","volume":"3","author":"Adler","year":"2000","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl. 1 Pt A","key":"10.1016\/j.pnpbp.2003.09.006_BIB2","doi-asserted-by":"crossref","first-page":"265A","DOI":"10.1097\/00002826-199201001-00138","article-title":"Limbic selective neuroleptics","volume":"15","author":"Bischoff","year":"1992","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/syn.890190102","article-title":"Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride","volume":"19","author":"Booze","year":"1995","journal-title":"Synapse"},{"issue":"Suppl. 3","key":"10.1016\/j.pnpbp.2003.09.006_BIB4","first-page":"190","article-title":"D2\/D3 receptor blockade induced by amisulpride treatment is limbic selective: preliminary [123I]epidepride findings","volume":"53","author":"Bressan","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0006-8993(80)91016-1","article-title":"Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat","volume":"192","author":"Carter","year":"1980","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00423298","article-title":"On the supersensitivity of dopamine receptors, induced by neuroleptics","volume":"48","author":"Christensen","year":"1976","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB7","first-page":"519","article-title":"Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors","volume":"232","author":"Claustre","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-2999(78)90251-0","article-title":"Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity","volume":"50","author":"Costall","year":"1978","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0006-8993(97)00649-5","article-title":"Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat","volume":"768","author":"Cudennec","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2165\/00003495-200161140-00014","article-title":"Amisulpride: a review of its use in the management of schizophrenia","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00423299","article-title":"Influence of pheniramine and chlorpheniramine on apomorphine induced compulsive gnawing in mice","volume":"48","author":"Dadkar","year":"1976","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1176\/ajp.156.4.610","article-title":"Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride","volume":"156","author":"Danion","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB13","first-page":"275","article-title":"Self-inhibitory dopamine receptors: their role in the biochemical and behavioral effects of low doses of apomorphine","volume":"19","author":"Di Chiara","year":"1978","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB14","first-page":"51","article-title":"Effects of acute and repeated administration of amisulpride, a dopamine D2\/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons","volume":"287","author":"Di Giovanni","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s002590050460","article-title":"In vivo effects of olanzapine on striatal dopamine D2\/D3 receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study","volume":"26","author":"Dresel","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/(SICI)1096-8628(19980710)81:4<318::AID-AJMG8>3.0.CO;2-P","article-title":"Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians","volume":"81","author":"Dubertret","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1471-4159.1991.tb08213.x","article-title":"Sigma receptors: from molecule to man","volume":"57","author":"Ferris","year":"1991","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00008877-200109000-00001","article-title":"Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194a: an analysis of possible mechanisms","volume":"12","author":"Goudie","year":"2001","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-002-1066-6","article-title":"Prolactin secretion is not a core dimension of \u201catypicality\u201d","volume":"162","author":"Grunder","year":"2002","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/archpsyc.1997.01830150047009","article-title":"Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study","volume":"54","author":"Gurevich","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB21","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/BF02244653","article-title":"Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats","volume":"110","author":"Guyon","year":"1993","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB22","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action","volume":"25","author":"Kapur","year":"2000","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1192\/bjp.180.5.465-a","article-title":"Atypical antipsychotics, cortical D(2) receptors and sensitivity to endogenous dopamine","volume":"180","author":"Kapur","year":"2002","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood\u2013brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01253110","article-title":"Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain","volume":"87","author":"K\u00f6hler","year":"1992","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s007020050091","article-title":"Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia","volume":"105","author":"Lahti","year":"1998","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB28","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/0014-2999(95)00106-U","article-title":"Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo","volume":"275","author":"Lejeune","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","article-title":"Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials","volume":"159","author":"Leucht","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.170.1.18","article-title":"Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia","volume":"170","author":"Loo","year":"1997","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1185\/030079902125001128","article-title":"A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months","volume":"18","author":"Martin","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF02245616","article-title":"In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia","volume":"124","author":"Martinot","year":"1996","journal-title":"Psychopharmacology (Berl.)"},{"issue":"4","key":"10.1016\/j.pnpbp.2003.09.006_BIB33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/026988110001400405","article-title":"D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study","volume":"14","author":"Meisenzahl","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","article-title":"The mechanism of action of novel antipsychotic drugs","volume":"17","author":"Meltzer","year":"1991","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0193-953X(18)30179-5","article-title":"New drugs for the treatment of schizophrenia","volume":"16","author":"Meltzer","year":"1993","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB36","first-page":"64","article-title":"Role of serotonin in the action of atypical antipsychotic drugs","volume":"3","author":"Meltzer","year":"1995","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB37","first-page":"885","volume":"275","author":"Millan","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB38","first-page":"31","article-title":"The influence of antiserotonergic agents on the action of dopaminergic drugs","volume":"29","author":"Mogilnicka","year":"1977","journal-title":"Pol. J. Pharmacol. Pharm."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/15622970009150570","article-title":"Definition, psychopharmacological basis and clinical evaluation of novel\/atypical neuroleptics: methodological issues and clinical consequences","volume":"1","author":"M\u00f6ller","year":"2000","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s004060170030","article-title":"Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia","volume":"251","author":"M\u00f6ller","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s002130050361","article-title":"Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol","volume":"132","author":"M\u00f6ller","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB42","first-page":"98","article-title":"Amisulprid. Pharmakologische Grundlagen der atypischen Eigenschaften","volume":"7","author":"M\u00fcller","year":"2000","journal-title":"Psychopharmakotherapie"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB43","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1176\/ajp.152.10.1444","article-title":"D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients","volume":"152","author":"Nordstrom","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB44","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1006\/nimg.2001.0879","article-title":"Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy\u2014a simulation study based on experimental data","volume":"14","author":"Olsson","year":"2001","journal-title":"Neuroimage"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB45","first-page":"73","article-title":"Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2\/D3 dopamine receptor antagonist activity and limbic selectivity","volume":"280","author":"Perrault","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-1781(99)00075-X","article-title":"Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia","volume":"88","author":"Peuskens","year":"1999","journal-title":"Psychiatry Res."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2003.09.006_BIB47","first-page":"305S","article-title":"Amisulpride improves affective symptoms in acute schizophrenia","volume":"2","author":"Peuskens","year":"2001","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0447.1998.tb10044.x","article-title":"Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol","volume":"98","author":"Puech","year":"1998","journal-title":"Acta Psychiatr. Scand."},{"issue":"Suppl. 3","key":"10.1016\/j.pnpbp.2003.09.006_BIB49","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/S0924-977X(02)80440-0","article-title":"Efficacy of amisulpride vs. risperidone in the long-term treatment of chronic schizophrenia: results from a 12 month double-blind study","volume":"12","author":"Rein","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.320","article-title":"A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers","volume":"17","author":"Rosenzweig","year":"2002","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s002130050255","article-title":"Discriminative stimulus effects of apomorphine and 7-OH-DPAT: a potential role for dopamine D3 receptors","volume":"130","author":"Sanger","year":"1997","journal-title":"Psychopharmacology (Berl.)"},{"issue":"Suppl. 9","key":"10.1016\/j.pnpbp.2003.09.006_BIB52","first-page":"5","article-title":"Pharmakologische Befunde mit Amisulprid","volume":"6","author":"Sanger","year":"1999","journal-title":"Psychopharmakotherapie"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB53","series-title":"Psychopharmacology of the Limbic System","first-page":"174","article-title":"Neuroleptics and the limbic system","author":"Scatton","year":"1985"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB54","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0014-2999(77)90301-6","article-title":"Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity","volume":"44","author":"Scatton","year":"1977","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2003.09.006_BIB55","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/00004850-199705002-00006","article-title":"Amisulpride: from animal pharmacology to therapeutic action","volume":"12","author":"Scatton","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB56","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","article-title":"The role of 5-HT2A receptors in antipsychotic activity","volume":"56","author":"Schmidt","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/026988110201600302","article-title":"Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine","volume":"16","author":"Schmitt","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB58","first-page":"83","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002826-199308000-00002","article-title":"Dopamine D3 receptor: basic and clinical aspects","volume":"16","author":"Schwartz","year":"1993","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-0173(99)00043-0","article-title":"Possible implications of the dopamine D-3 receptor in schizophrenia and in antipsychotic drug actions","volume":"31","author":"Schwartz","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB62","first-page":"261","article-title":"Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4","volume":"7","author":"Seeman","year":"1992","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB64","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/ajp.156.6.876","article-title":"Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine","volume":"156","author":"Seeman","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/347146a0","article-title":"Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics","volume":"347","author":"Sokoloff","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0922-4106(92)90107-7","article-title":"Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor","volume":"225","author":"Sokoloff","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB67","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0006-2952(92)90227-A","article-title":"The third dopamine receptor (D3) as a novel target for antipsychotics","volume":"43","author":"Sokoloff","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB68","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0306-4522(91)90277-U","article-title":"Presynaptic autoinhibition of the electrically evoked dopamine release studied in the rat olfactory tubercle by in vivo electrochemistry","volume":"45","author":"Suaud-Chagny","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB69","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/350614a0","article-title":"Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1","volume":"350","author":"Sunahara","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-2999(94)90718-8","article-title":"Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors","volume":"263","author":"Svensson","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB71","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00213-002-1082-6","article-title":"Striatal dopamine-2 receptor occupancy as measured with [(123)I]Iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol","volume":"162","author":"Tauscher","year":"2002","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB72","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/BF00175707","article-title":"Effects of D-2 agonists on the release of dopamine: localization of the mechanism of action","volume":"342","author":"Timmerman","year":"1990","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB73","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","article-title":"Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine","volume":"350","author":"Van Tol","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB74","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF00501198","article-title":"Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice","volume":"329","author":"Vasse","year":"1985","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"issue":"Suppl. 5","key":"10.1016\/j.pnpbp.2003.09.006_BIB75","first-page":"262P","article-title":"D2-like dopamine receptor occupancy in schizophrenic patients treated with amisulpride: a PET study with 18F-desmethoxyfallypride","volume":"43","author":"Vernaleken","year":"2002","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF01244979","article-title":"The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity","volume":"94","author":"Waters","year":"1993","journal-title":"J. Neural Transm. Gen Sect."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(94)90399-9","article-title":"Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo","volume":"251","author":"Waters","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0022-3956(94)90004-3","article-title":"Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers","volume":"28","author":"Wetzel","year":"1994","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002130050614","article-title":"Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology\u2014a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-\/D2-like antagonist","volume":"137","author":"Wetzel","year":"1998","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0091-3057(83)90304-0","article-title":"Facilitation by alpha-adrenolytics of apomorphine gnawing behaviour: depression of threshold apomorphine concentration in the striatum of the rat","volume":"19","author":"Wiszniowska-Szafraniec","year":"1983","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB81","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(98)00174-5","article-title":"Atypical antipsychotic-like effects of the dopamine D3 receptor agonist (+)-PD 128,907","volume":"347","author":"Witkin","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004714-200104000-00013","article-title":"In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia","volume":"21","author":"Xiberas","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.09.006_BIB83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.179.6.503","article-title":"Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia","volume":"179","author":"Xiberas","year":"2001","journal-title":"Br. J. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584603002197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584603002197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T07:48:57Z","timestamp":1682581737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584603002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":83,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["S0278584603002197"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2003.09.006","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2003,10]]}}}